October 25, 2024

Cancer Diagnostics Market is set to record 8.4% CAGR by 2030

Cancer Diagnostics Market size is expected to grow Usd 261.34 bn by 2030 at a CAGR of 8.4% over the forecast period 2021 – 2030.

A new study on the global Cancer Diagnostics market has been published by Precedence Research. It presents a wealth of information on key market dynamics, including the drivers, market trends, and challenges, as well as the structure of the global Cancer Diagnostics market. The study offers valuable information about the global Cancer Diagnostics market to illustrate how the market would grow during the forecast period 2021-2030. The report provides the value and volume of the global Cancer Diagnostics market for the period 2021–2030, considering 2019 as the base year and 2030 as the forecast year. The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments and sub-segments included in the scope of the study.

Key indicators of market growth, which include value chain as well as supply chain analyses, and Compound Annual Growth Rate (CAGR), are elucidated in the study in a comprehensive manner. This data can help readers interpret quantitative growth aspects of the global Cancer Diagnostics market during the forecast period.

Get the Sample Pages of Report@ https://www.precedenceresearch.com/sample/1194

An extensive analysis on business strategies of leading market players is also featured in study on the global Cancer Diagnostics market. This can help readers understand principal factors to foresee growth in the global Cancer Diagnostics market. In this study, readers can also find specific data on the qualitative and quantitative growth avenues for the global market, which is expected to guide market players in making apt decisions in the future.

The report also delves into the competition landscape of the global Cancer Diagnostics market. Key players operating in the global market have been identified, and each one of these has been profiled for their distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global market report.

Key Players

  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific, Inc.
  • Illumina, Inc.
  • Becton, Dickinson and Company
  • GE Healthcare
  • QIAGEN N.V.
  • Abbott Laboratories, Inc.
  • Roche Diagnostics
  • Siemens Healthcare
  • Philips Healthcare
  • R. Bard, Inc.
  • Others

Key Questions Answered in Cancer Diagnostics Market Study

– What are the key factors influencing the Cancer Diagnostics market in each region?

– What will be the CAGR of the global Cancer Diagnostics market between 2017 and 2030?

– What is the future scope and changing trends in technologies in the global Cancer Diagnostics market?

– Which factors will impede the growth of the global Cancer Diagnostics market during the forecast period?

– Which are the leading companies in the global Cancer Diagnostics market?

– Which region is set to expand at the fastest CAGR during the forecast period?

– What is the volume (Units) of different Cancer Diagnostics across all regions during the forecast period?

– Which segment will have the highest revenue globally in 2030 and which segment will expand at the fastest CAGR during the forecast period?

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1194

Research Methodology

A unique research methodology has been utilized by precedence research to conduct a comprehensive research on the growth of the global Cancer Diagnostics market and arrive at conclusions on the future growth prospects of the market. This research methodology is a combination of primary and secondary research, which helps analysts warrant the accuracy and reliability of the drawn conclusions.

Secondary sources referred to by analysts during the production of the global Cancer Diagnostics market report include statistics from company annual reports, SEC filings, company websites, World Bank database, investor presentations, regulatory databases, government publications, and industry white papers. Analysts have also interviewed senior managers, product portfolio managers, CEOs, VPs, and market intelligence managers, who contributed to the production of our study on the market as a primary source.

These primary and secondary sources provided exclusive information during interviews, which serves as a validation from Cancer Diagnostics industry leaders. Access to an extensive internal repository and external proprietary databases allows this report to address specific details and questions about the global market with accuracy. The study also uses the top-down approach to assess the numbers for each segment and the bottom-up approach to counter-validate them. This has helped in making precedence research estimates on the future prospects of the global market more reliable and accurate.

Segmentation

By Test Type

  • Laboratory Tests
  • Genetic Tests
  • Imaging
  • Endoscopy
  • Biopsy
  • Others (barium enema)

By Application

  • Breast Cancer
  • Colorectal Cancer
  • Cervical Cancer
  • Lung Cancer
  • Prostate Cancer
  • Skin Cancer
  • Blood Cancer
  • Kidney Cancer
  • Liver Cancer
  • Pancreatic Cancer
  • Ovarian Cancer
  • Others

By Regional Outlook

  • North America
    • US.
    • Canada
  • Europe
    • UK.
    • Germany
    • France
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
  • Rest of the World

Table of Content

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Cancer Diagnostics Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Cancer Diagnostics Market

5.1. Covid-19: Cancer Diagnostics Industry Impact
5.2. Cancer Diagnostics Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Cancer Diagnostics Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Cancer Diagnostics Market Players to deal with Covid-19 Pandemic Scenario

Chapter 6. Cancer Diagnostics Market Dynamics Analysis and Trends

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Driver 1
6.1.1.2. Driver 2
6.1.2. Market Restraints
6.1.2.1. Restraint 1
6.1.3. Market Opportunities
6.1.3.1. Opportunity 1
6.1.3.2. Opportunity 2

Chapter 7. Global Cancer Diagnostics Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Cancer Diagnostics Market Revenue by Market Players (2015-2020)
7.1.1.2. Cancer Diagnostics Market Revenue Market Share by Market Players (2015-2020)
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Product Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Product Type Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Cancer Diagnostics Market, By Product Type

8.1. Cancer Diagnostics Market, by Product Type, 2016-2027
8.1.1. Laboratory Tests
8.1.1.1. Market Revenue and Forecast (2016-2027)
8.1.2. Genetic Tests
8.1.2.1. Market Revenue and Forecast (2016-2027)
8.1.3. Imaging
8.1.3.1. Market Revenue and Forecast (2016-2027)
8.1.4. Endoscopy
8.1.5. Biopsy
8.1.6. Others (barium enema)

Chapter 9. Global Cancer Diagnostics Market, By Application

9.1. Cancer Diagnostics Market, by Application, 2016-2027
9.1.1. Breast Cancer
9.1.1.1. Market Revenue and Forecast (2016-2027)
9.1.2. Colorectal Cancer
9.1.2.1. Market Revenue and Forecast (2016-2027)
9.1.3. Cervical Cancer
9.1.3.1. Market Revenue and Forecast (2016-2027)
9.1.4. Lung Cancer
9.1.4.1. Market Revenue and Forecast (2016-2027)
9.1.5. Prostate Cancer
9.1.6. Skin Cancer
9.1.7. Blood Cancer
9.1.8. Kidney Cancer
9.1.9. Liver Cancer
9.1.10. Pancreatic Cancer
9.1.11. Ovarian Cancer
9.1.12. Others

Chapter 10. Global Cancer Diagnostics Market, Regional Estimates and Trend Forecast

10.1. North America
10.1.1. Market Revenue Forecast by Product Type(2016-2027)
10.1.2. Market Revenue Forecast by Application (2016-2027)
10.1.3. U.S
10.1.3.1. Market Revenue Forecast (2016-2027)
10.1.4. Canada
10.1.4.1. Market Revenue Forecast (2016-2027)
10.2. Europe
10.2.1. Market Revenue Forecast by Product Type(2016-2027)
10.2.2. Market Revenue Forecast by Application (2016-2027)
10.2.3. UK
10.2.3.1. Market Revenue Forecast (2016-2027)
10.2.4. Germany
10.2.4.1. Market Revenue Forecast (2016-2027)
10.2.5. France
10.2.5.1. Market Revenue Forecast (2016-2027)
10.2.6. Rest of EU
10.2.6.1. Market Revenue Forecast (2016-2027)
10.3. Asia Pacific (APAC)
10.3.1. Market Revenue Forecast by Product Type(2016-2027)
10.3.2. Market Revenue Forecast by Application (2016-2027)
10.3.3. China
10.3.3.1. Market Revenue Forecast (2016-2027)
10.3.4. India
10.3.4.1. Market Revenue Forecast (2016-2027)
10.3.5. Japan
10.3.5.1. Market Revenue Forecast (2016-2027)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue Forecast (2016-2027)
10.4. LATAM
10.4.1. Market Revenue Forecast by Product Type(2016-2027)
10.4.2. Market Revenue Forecast by Application (2016-2027)
10.4.3. Brazil
10.4.3.1. Market Revenue Forecast (2016-2027)
10.4.4. Rest of LATAM
10.4.4.1. Market Revenue Forecast (2016-2027)
10.5. Middle East and Africa (MEA)
10.5.1. Market Revenue Forecast by Product Type(2016-2027)
10.5.2. Market Revenue Forecast by Application (2016-2027)
10.5.3. GCC
10.5.3.1. Market Revenue Forecast (2016-2027)
10.5.4. North Africa
10.5.4.1. Market Revenue Forecast (2016-2027)
10.5.5. South Africa
10.5.5.1. Market Revenue Forecast (2016-2027)
10.5.6. Rest of MEA
10.5.6.1. Market Revenue Forecast (2016-2027)

Chapter 11. Company Profiles

11.1. Agilent Technologies, Inc.
11.1.1. Company Overview, Business Information, Regional Presence
11.1.2. Product Portfolio Analysis
11.1.2.1. Product Details, Specification, Application
11.1.3. Revenue, Price, and Gross Margin (2015-2020)
11.1.4. Recent Developments and Strategies
11.2. Thermo Fisher Scientific, Inc.
11.2.1. Company Overview, Business Information, Regional Presence
11.2.2. Product Portfolio Analysis
11.2.2.1. Product Details, Specification, Application
11.2.3. Revenue, Price, and Gross Margin (2015-2020)
11.2.4. Recent Developments and Strategies
11.3. Illumina, Inc.
11.3.1. Company Overview, Business Information, Regional Presence
11.3.2. Product Portfolio Analysis
11.3.2.1. Product Details, Specification, Application
11.3.3. Revenue, Price, and Gross Margin (2015-2020)
11.3.4. Recent Developments and Strategies
11.4. Becton, Dickinson and Company
11.4.1. Company Overview, Business Information, Regional Presence
11.4.2. Product Portfolio Analysis
11.4.2.1. Product Details, Specification, Application
11.4.3. Revenue, Price, and Gross Margin (2015-2020)
11.4.4. Recent Developments and Strategies
11.5. GE Healthcare
11.5.1. Company Overview, Business Information, Regional Presence
11.5.2. Product Portfolio Analysis
11.5.2.1. Product Details, Specification, Application
11.5.3. Revenue, Price, and Gross Margin (2015-2020)
11.5.4. Recent Developments and Strategies
11.6. QIAGEN N.V.
11.6.1. Company Overview, Business Information, Regional Presence
11.6.2. Product Portfolio Analysis
11.6.2.1. Product Details, Specification, Application
11.6.3. Revenue, Price, and Gross Margin (2015-2020)
11.6.4. Recent Developments and Strategies
11.7. Abbott Laboratories, Inc.
11.7.1. Company Overview, Business Information, Regional Presence
11.7.2. Product Portfolio Analysis
11.7.2.1. Product Details, Specification, Application
11.7.3. Revenue, Price, and Gross Margin (2015-2020)
11.7.4. Recent Developments and Strategies
11.8. Roche Diagnostics
11.8.1. Company Overview, Business Information, Regional Presence
11.8.2. Product Portfolio Analysis
11.8.2.1. Product Details, Specification, Application
11.8.3. Revenue, Price, and Gross Margin (2015-2020)
11.8.4. Recent Developments and Strategies
11.9. Siemens Healthcare
11.9.1. Company Overview, Business Information, Regional Presence
11.9.2. Product Portfolio Analysis
11.9.2.1. Product Details, Specification, Application
11.9.3. Revenue, Price, and Gross Margin (2015-2020)
11.9.4. Recent Developments and Strategies
11.10. Philips Healthcare
11.10.1. Company Overview, Business Information, Regional Presence
11.10.2. Product Portfolio Analysis
11.10.2.1. Product Details, Specification, Application
11.10.3. Revenue, Price, and Gross Margin (2015-2020)
11.10.4. Recent Developments and Strategies

Chapter 12. Appendix

12.1. About Us
12.2. Glossary of Terms

Get Full Access of this Research Report, Click here@ https://www.precedenceresearch.com/checkout/1194

Contact Us:

Precedence Research

Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada

Call: +1 9197 992 333

Email: sales@precedenceresearch.com

Website: https://www.precedenceresearch.com

Blog:https://precedenceresearchreport.wordpress.com

Follow us on LinkedIn | Twitter | Facebook

Leave a Reply

Your email address will not be published. Required fields are marked *